Table 1 JAK inhibitors approved and in development

From: The emerging safety profile of JAK inhibitors in rheumatic disease

Compound Target Indication Stage of development
ABT-494 JAK1 RA Phase I
Crohn's disease Phase II
Ulcerative colitis Phase II
Atopic dermatitis Phase I
Baricitinib JAK1, JAK2 RA Phase III
Psoriasis Phase II
Diabetic nephropathy Phase II
SLE Phase II
Atopic dermatitis Phase II
Decernotinib JAK3 RA Phase II (development currently on hold)
CYT387 JAK1, JAK2 Myelofibrosis Phase I–II
Filgotinib JAK1 RA Phase III
Crohn's disease Phase III
Ulcerative colitis Phase III
INCB018424 JAK1, JAK2 Psoriasis (topical treatment) Phase II
Pacritinib JAK2 Myelofibrosis Phase II
Peficitinib JAK1, JAK3 RA Phase III
Psoriasis Phase II
Ruxolitinib JAK1, JAK2 Myelofibrosis Approved by FDA
Tofacitinib JAK1, JAK3 RA Approved by FDA
Psoriasis Phase III
Ulcerative colitis Phase III ongoing
JIA Phase I
  1. JAK, Janus kinase; JIA, juvenile idiopathic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
PowerPoint slide